Expression of C-X-C chemokine receptor types 1/2 in patients with gastric carcinoma: Clinicopathological correlations and significance

Wang,Jun Pu; Hu,Wan Ming; Wang,Kuan Song; Yu,Jun; Luo,Bai Hua; Wu,Chang; Chen,Zhi Hong; Luo,Geng Qiu; Liu,Yu Wu; Liu,Qin Lai; Xiao,Yan; Zhou,Hai Yan; Yang,Xiao Jing; Jiang,Hai Ying; Li,Jing He; Wen,Ji Fang

doi:10.3892/ol.2012.1043

Expression of C-X-C chemokine receptor types 1/2 in patients with gastric carcinoma: Clinicopathological correlations and significance

Authors:
- Jun Pu Wang
- Wan Ming Hu
- Kuan Song Wang
- Jun Yu
- Bai Hua Luo
- Chang Wu
- Zhi Hong Chen
- Geng Qiu Luo
- Yu Wu Liu
- Qin Lai Liu
- Yan Xiao
- Hai Yan Zhou
- Xiao Jing Yang
- Hai Ying Jiang
- Jing He Li
- Ji Fang Wen
View Affiliations

Affiliations: Department of Pathology, School Of Basic Medicine, Central South University, Hunan, Changsha 410013, P.R. China, Third Xiang-ya Hospital, Central South University, Hunan, Changsha 410013, P.R. China
Published online on: November 23, 2012 https://doi.org/10.3892/ol.2012.1043
Pages: 574-582

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

C-X-C chemokine receptor types 1/2 (CXCR1/2) may play multiple roles in the development and progression of a number of types of tumor. The abnormal expression of CXCR1/2 in various types of malignant tumors has been reported, but less is known with regard to gastric carcinoma. The present study was preliminarily conducted to elucidate the correlation between clinicopathological factors and the immunohistochemical expression of CXCR1/2 in patients with gastric carcinoma. The expression of CXCR1/2 in 69 specimens of sporadic gastric carcinoma and their corresponding non-neoplastic mucosa obtained by gastrectomy was assayed by immunohistochemistry (IHC) using a polyclonal anti-CXCR1/2 antibody. ERK1/2 and AKT phosphorylation and the expression of indicators of proliferation, growth and apoptosis (Bcl-2 and Bax, Cyclin D1, EGFR and Ki-67), angiogenesis (VEGF and CD34), invasion and metastasis (MMP-9, MMP-2, TIMP-2 and E-cadherin) were also detected by IHC. A total of 68 (98.6%) of the 69 patients with gastric carcinoma were found to have positive CXCR1/2 expression, which appeared to be significantly higher in gastric carcinoma compared with corresponding non-neoplastic mucosa tissues. The expression of CXCR1/2 in gastric carcinoma was significantly associated with invasion, metastasis and TNM staging (P<0.001). Correlation analysis between CXCR1/2 and pAKT (P=0.032), pERK (P<0.001), Cyclin D1 (P=0.049), EGFR (P=0.013), Bcl-2 (P=0.003), microvessel density (P=0.001), MMP-9 (P=0.013) and MMP-2 (P=0.027) expression using the Spearman test showed significant correlation in gastric carcinoma. Univariate and multivariate logistic regression analysis showed that, compared with negative or weak expression, overexpression of CXCR1/2 protein was a significant risk factor for TNM stage (P<0.001). These results preliminarily suggest that CXCR1/2 may be a useful maker for progression of the tumors and a promising target for gastric carcinoma therapy.

View Figures

View References

1.	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010, http://globocan.iarc.fr. accessed on February 27, 2012.
2.	Alberts SR, Cervantes A and van de Velde CJ: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 14(Suppl 2): ii31–36. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol. 12:17–20. 2006.
4.	Hyung WJ, Noh SH, Yoo CH, et al: Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg. 26:323–329. 2002. View Article : Google Scholar : PubMed/NCBI
5.	Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Nathan C and Ding A: Nonresolving inflammation. Cell. 140:871–882. 2010. View Article : Google Scholar
7.	Mantovani A: Cancer: Inflaming metastasis. Nature. 457:36–37. 2009. View Article : Google Scholar
8.	Righi E, Kashiwagi S, Yuan J, et al: CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 71:5522–5534. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Wendel C, Hemping-Bovenkerk A, Krasnyanska J, et al: CXCR4/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model. PLoS One. 7:e300462012. View Article : Google Scholar : PubMed/NCBI
10.	Balkwill FR: The chemokine system and cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar
11.	Lazennec G and Richmond A: Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 16:133–144. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Murphy PM: The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol. 12:593–633. 1994. View Article : Google Scholar : PubMed/NCBI
13.	Kelvin DJ, Michiel DF, Johnston JA, et al: Chemokines and serpentines: the molecular biology of chemokine receptors. J Leukoc Biol. 54:604–612. 1993.PubMed/NCBI
14.	Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Zhang Y, Wang L, Zhang M, Jin M, Bai C and Wang X: Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J Cell Physiol. 227:35–43. 2012. View Article : Google Scholar : PubMed/NCBI
16.	Ginestier C, Liu S, Diebel ME, et al: CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 120:485–497. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Singh S, Nannuru KC, Sadanandam A, Varney ML and Singh RK: CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer. 100:1638–1646. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R and Singh RK: Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett. 300:180–188. 2011. View Article : Google Scholar : PubMed/NCBI
19.	Matsuo Y, Raimondo M, Woodward TA, et al: CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer. 125:1027–1037. 2009. View Article : Google Scholar : PubMed/NCBI
20.	Eck M, Schmausser B, Scheller K, Brändlein S and Müller-Hermelink HK: Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol. 134:508–515. 2003. View Article : Google Scholar : PubMed/NCBI
21.	Wang JP, Hu WM, Wang KS, et al: Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma. Exp Ther Med. 4:55–60. 2012.PubMed/NCBI
22.	Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 17:3077–3079. 2010. View Article : Google Scholar : PubMed/NCBI
23.	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI
24.	Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481. 1999.PubMed/NCBI
25.	Raman D, Baugher PJ, Thu YM and Richmond A: Role of chemokines in tumor growth. Cancer Lett. 256:137–165. 2007. View Article : Google Scholar : PubMed/NCBI
26.	Ali S and Lazennec G: Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev. 26:401–420. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Vindrieux D, Escobar P and Lazennec G: Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer. 16:663–673. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005. View Article : Google Scholar
29.	Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E and Sipkins DA: Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 322:1861–1865. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Singh S, Varney M and Singh RK: Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69:411–415. 2009. View Article : Google Scholar : PubMed/NCBI
31.	Kitamura T, Kometani K, Hashida H, et al: SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet. 39:467–475. 2007.
32.	Buonamici S, Trimarchi T, Ruocco MG, et al: CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature. 459:1000–1004. 2009. View Article : Google Scholar : PubMed/NCBI
33.	Maxwell PJ, Gallagher R, Seaton A, et al: HIF-1 and NF-kappa B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 26:7333–7345. 2007. View Article : Google Scholar : PubMed/NCBI
34.	Varney ML, Li A, Dave BJ, Bucana CD, Johansson SL and Singh RK: Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis. 20:723–731. 2003. View Article : Google Scholar : PubMed/NCBI
35.	Varney ML, Johansson SL and Singh RK: Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol. 125:209–216. 2006. View Article : Google Scholar : PubMed/NCBI
36.	Murphy C, McGurk M, Pettigrew J, et al: Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res. 11:4117–4127. 2005. View Article : Google Scholar : PubMed/NCBI
37.	Müller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001.PubMed/NCBI
38.	Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H and Miyasaka M: Chemokines in tumor progression and metastasis. Cancer Sci. 96:317–322. 2005. View Article : Google Scholar : PubMed/NCBI
39.	Koizumi K, Hojo S, Akashi T, Yasumoto K and Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 98:1652–1658. 2007. View Article : Google Scholar : PubMed/NCBI
40.	Balakin KV, Ivanenkov YA, Tkachenko SE, Kiselyov AS and Ivachtchenko AV: Regulators of chemokine receptor activity as promising anticancer therapeutics. Curr Cancer Drug Targets. 8:299–340. 2008. View Article : Google Scholar : PubMed/NCBI
41.	Ruffini PA, Morandi P, Cabioglu N, Altundag K and Cristofanilli M: Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer. 109:2392–2404. 2007. View Article : Google Scholar : PubMed/NCBI
42.	Kakinuma T and Hwang ST: Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol. 79:639–651. 2006. View Article : Google Scholar : PubMed/NCBI
43.	Gabellini C, Trisciuoglio D, Desideri M, et al: Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer. 45:2618–2627. 2009. View Article : Google Scholar : PubMed/NCBI
44.	Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
45.	Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep. 21:1323–1333. 2009.PubMed/NCBI
46.	Knall C, Worthen GS and Johnson GL: Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases. Proc Natl Acad Sci USA. 94:3052–3057. 1997. View Article : Google Scholar
47.	Cheng GZ, Park S, Shu S, et al: Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Current Cancer Drug Targets. 8:2–6. 2008. View Article : Google Scholar : PubMed/NCBI
48.	MacManus CF, Pettigrew J, Seaton A, et al: Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res. 5:737–748. 2007. View Article : Google Scholar : PubMed/NCBI
49.	Venkatakrishnan G, Salgia R and Groopman JE: Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 275:6868–6875. 2000. View Article : Google Scholar
50.	Luppi F, Longo AM, de Boer WI, Rabe KF and Hiemstra PS: Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer. 56:25–33. 2007. View Article : Google Scholar : PubMed/NCBI